Respiratory Medicine
Volume 103, Issue 7 , Pages 963-974, July 2009

Smoking cessation in chronic obstructive pulmonary disease

  • Donald P. Tashkin

      Affiliations

    • Department of Medicine, David Geffen School of Medicine at UCLA, 37-131 Center for Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095-1690, USA
    • Corresponding Author InformationCorresponding author. Tel.: +310 825 3163; fax: +310 206 5088.
  • ,
  • Robert P. Murray

      Affiliations

    • Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, MS7, 820 Sherbrook Street, Winnipeg, MB R3A 1R9, Canada

Received 24 September 2008; accepted 19 February 2009. published online 16 March 2009.

Summary 

Chronic obstructive pulmonary disease (COPD) is increasing in prevalence, and is predicted to become the third leading cause of deaths worldwide by 2020. The precise prevalence of COPD is not known, as many individuals with the disease are left undiagnosed, despite the requirement of only simple spirometry testing for disease detection. The major risk factor for the development of COPD is cigarette smoking, with 90% of deaths from COPD directly attributable to smoking. Therefore smoking cessation is the most effective means of halting or slowing the progress of this disease.

This review summarizes and compares the differential characteristics of smokers with COPD vs. those without COPD in relation to their smoking behavior and quitting attempts, and discusses the various strategies that can be used to help patients quit and improve their likelihood of long-term smoking cessation. Of the various behavioral interventions available that can increase the likelihood of smoking cessation, one of the simplest and most effective strategies that physicians can use is simply to advise their patients to quit, particularly if this advice is combined with informing the patients of their “lung age”. We also discuss the pharmacologic therapies used to enhance the likelihood of quitting, including nicotine replacement, bupropion SR and varenicline, along with novel nicotine vaccines, which are currently undergoing clinical trials.

Keywords: Smoking, Smoking cessation, Chronic obstructive pulmonary disease, Lung age

Abbreviations: CI, confidence interval, COPD, chronic obstructive pulmonary disease, DALYs, disability-adjusted life years, FEV1, forced expired volume in 1s, FVC, forced vital capacity, GOLD, Global Initiative for Chronic Obstructive Lung Disease, LHS, Lung Health Study, LRI, lower respiratory illness, NHANES, National Health and Nutrition Examination Survey, NRT, nicotine replacement therapy, OR, odds ratio, SD, standard deviation, SR, sustained release

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0954-6111(09)00065-1

doi:10.1016/j.rmed.2009.02.013

Respiratory Medicine
Volume 103, Issue 7 , Pages 963-974, July 2009